Literature DB >> 24583239

Pharmacokinetic comparison of seven major bio-active components in normal and blood deficiency rats after oral administration of Danggui Buxue decoction by UPLC-TQ/MS.

Xuqin Shi1, Yuping Tang2, Huaxu Zhu1, Weixia Li1, Wei Li1, Zhenhao Li1, Niancui Luo1, Jin-ao Duan1.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Blood deficiency is commonly encountered among women, and is the root of many gynecological disorders. Danggui Buxue Decoction (DBD), a classical traditional Chinese formula which is composed of Astragali Radix (AR) and Angelicae Sinensis Radix (ASR) at the ratio of 5:1 (w/w), is widely used in TCM clinics for treatment of blood deficiency syndrome. This study is to compare the in vivo pharmacokinetic properties of seven major bio-active components in normal and blood deficiency rats after oral administration of DBD.
MATERIALS AND METHODS: Blood deficiency rats were induced by bleeding from orbit at the dosages of 5.0mL/kg each day for 12 days. Normal and blood deficiency rats were administrated of DBD on the 12th day at the dosage of 20g/kg, and blood was collected at different time points after then. Concentrations of ferulic acid, caffeic acid, butylphthalide, ligustilide, calycosin-7-O-β-glucoside, ononin, and astragaloside IV in plasma were quantified by UPLC-TQ/MS, and the main pharmacokinetic parameters were calculated by DAS 2.0.
RESULTS: It was found that Cmax, Tmax and MRT0~T of astragaloside IV, Cmax, T1/2Z, AUC0~T and MRT0~T of calycosin-7-O-β-glucoside, T1/2Z and AUC0~T of ferulic acid, T1/2Z, AUC0~T and MRT0~T of ononin, and MRT0~T of ligustilide, butylphthalide, and caffeic acid in blood deficiency rats was significantly different (P<0.05) from normal rats.
CONCLUSIONS: This study was the first report about pharmacokinetic investigation in blood deficiency animals which was conducted by bleeding. And the results demonstrated that the seven DBD constituents in normal and blood deficiency rats had obvious differences in some pharmacokinetic characteristics, suggesting that the rate and extent of drug metabolism were altered in blood deficiency animals.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Astragaloside IV (PubChem CID: 13943297); Bleeding; Blood deficiency; Butylphthalide (PubChem CID: 61361); Caffeic acid (PubChem CID: 689043); Calycosin-7-O-β-glucoside ( PubChem CID: 44257232); Comparison; Danggui Buxue Decoction; Ferulic acid (PubChem CID: 445858); Ligustilide (PubChem CID: 5319022); Ononin (PubChem CID: 442813); Pharmacokinetic; UPLC-TQ/MS

Mesh:

Substances:

Year:  2014        PMID: 24583239     DOI: 10.1016/j.jep.2014.02.004

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  10 in total

1.  A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo.

Authors:  Tao Guo; Zu-Long Liu; Qiang Zhao; Zhi-Min Zhao; Cheng-Hai Liu
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

2.  The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage.

Authors:  Haigang Li; Yang Wang; Rong Fan; Huiying Lv; Hua Sun; Haitang Xie; Tao Tang; Jiekun Luo; Zian Xia
Journal:  Drug Des Devel Ther       Date:  2016-07-06       Impact factor: 4.162

3.  Integrated metabonomic-proteomic studies on blood enrichment effects of Angelica sinensis on a blood deficiency mice model.

Authors:  Yongli Hua; Wangling Yao; Peng Ji; Yanming Wei
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

4.  Network Pharmacology-Based Strategy Reveals the Effects of Hedysarum multijugum Maxim.-Radix Salviae Compound on Oxidative Capacity and Cardiomyocyte Apoptosis in Rats with Diabetic Cardiomyopathy.

Authors:  Shiying Zhang; Zhiying Yuan; Huaying Wu; Weiqing Li; Liang Li; Huiyong Huang
Journal:  Biomed Res Int       Date:  2020-10-17       Impact factor: 3.411

5.  Exploring the Oxidative Stress Mechanism of Buyang Huanwu Decoction in Intervention of Vascular Dementia Based on Systems Biology Strategy.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Yaqiao Yi; Shanshan Wang; Jinwen Ge
Journal:  Oxid Med Cell Longev       Date:  2021-03-03       Impact factor: 6.543

6.  Deciphering the Underlying Mechanisms of Formula Le-Cao-Shi Against Liver Injuries by Integrating Network Pharmacology, Metabonomics, and Experimental Validation.

Authors:  Qing Zhao; Xia Ren; Shu-Yue Song; Ri-Lei Yu; Xin Li; Peng Zhang; Chang-Lun Shao; Chang-Yun Wang
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

7.  Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury's Biological Network Based on Systematic Pharmacology.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Yi Chen; Shanshan Wang; Xiaofei Zhu; Jinwen Ge
Journal:  Front Pharmacol       Date:  2021-06-25       Impact factor: 5.810

8.  Integrated Metabolomics and Network Pharmacology Approach to Explain Possible Action Mechanisms of Xin-Sheng-Hua Granule for Treating Anemia.

Authors:  Han-Qing Pang; Shi-Jun Yue; Yu-Ping Tang; Yan-Yan Chen; Ya-Jie Tan; Yu-Jie Cao; Xu-Qin Shi; Gui-Sheng Zhou; An Kang; Sheng-Liang Huang; Ya-Jun Shi; Jing Sun; Zhi-Shu Tang; Jin-Ao Duan
Journal:  Front Pharmacol       Date:  2018-03-02       Impact factor: 5.810

9.  The Effect of Hedysarum multijugum Maxim.-Chuanxiong rhizoma Compound on Ischemic Stroke: A Research Based on Network and Experimental Pharmacology.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Yongmei Shi; Xiaofei Zhu; Wenlong Liu; Jinwen Ge
Journal:  Oxid Med Cell Longev       Date:  2020-10-06       Impact factor: 6.543

10.  Integrating systematic biological and proteomics strategies to explore the pharmacological mechanism of danshen yin modified on atherosclerosis.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Xiaoping Pan; Tingting Bao; Zhiyong Long; Qiaozhen Tong; Mengxia Yuan; Xiaofei Zhu; Jinwen Ge; Zhengde Huang
Journal:  J Cell Mol Med       Date:  2020-11-02       Impact factor: 5.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.